Next-Generation Phosphate Binders: Focus on Iron-Based Binders

详细信息    查看全文

• 作者：Dimitra Nastou (1) r> Beatriz Fernández-Fernández (2) (3) r> Usama Elewa (2) (3) r> Liliana González-Espinoza (2) (3) r> Emilio González-Parra (2) (3) r> Maria D. Sanchez-Ni?o (3) (4) r> Alberto Ortiz (2) (3) (5) r>
• 刊名：Drugs
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：74
• 期：8
• 页码：863-877
• 全文大小：
• 参考文献：1. Gonzalez-Parra E, Tu?ón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovasc Pathol. 2012;21:372-1. rnal" href="http://dx.doi.org/10.1016/j.carpath.2012.02.008" target="_blank" title="It opens in new window">CrossRef r> 2. Ellam TJ, Chico TJ. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis. 2012;220:310-. rnal" href="http://dx.doi.org/10.1016/j.atherosclerosis.2011.09.002" target="_blank" title="It opens in new window">CrossRef r> 3. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268-7. rnal" href="http://dx.doi.org/10.1016/S0140-6736(13)60897-1" target="_blank" title="It opens in new window">CrossRef r> 4. Ortiz A, Sanchez-Ni?o MD. The demise of calcium-based phosphate binders. Lancet. 2013;382:1232-. rnal" href="http://dx.doi.org/10.1016/S0140-6736(13)61165-4" target="_blank" title="It opens in new window">CrossRef r> 5. Itkonen ST, Karp HJ, Kemi VE, Kokkonen EM, Saarnio EM, Pekkinen MH, K?rkk?inen MU, Laitinen EK, Turanlahti MI, Lamberg-Allardt CJ. Associations among total and food additive phosphorus intake and carotid intima-media thickness—a cross-sectional study in a middle-aged population in Southern Finland. Nutr J. 2013;12:94. rnal" href="http://dx.doi.org/10.1186/1475-2891-12-94" target="_blank" title="It opens in new window">CrossRef r> 6. Waheed AA, Pedraza F, Lenz O, Isakova T. Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant. 2013;28:2961-. rnal" href="http://dx.doi.org/10.1093/ndt/gft244" target="_blank" title="It opens in new window">CrossRef r> 7. Forster I, Hernando N, Sorribas V, Werner A. Phosphate transporters in renal, gastrointestinal, and other tissues. Adv Chronic Kidney Dis. 2011;18:63-6. rnal" href="http://dx.doi.org/10.1053/j.ackd.2011.01.006" target="_blank" title="It opens in new window">CrossRef r> 8. Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant. 2013;28:2228-6. rnal" href="http://dx.doi.org/10.1093/ndt/gft065" target="_blank" title="It opens in new window">CrossRef r> 9. Moreno JA, Izquierdo MC, Sanchez-Ni?o MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011;22:1315-5. rnal" href="http://dx.doi.org/10.1681/ASN.2010101073" target="_blank" title="It opens in new window">CrossRef r> 10. Izquierdo MC, Sanz AB, Sánchez-Ni?o MD, Pérez-Gómez MV, Ruiz-Ortega M, Poveda J, Ruiz-Andrés O, Ramos AM, Moreno JA, Egido J, et al. Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing. Nefrologia. 2012;32:715-3. r> 11. Izquierdo MC, Perez-Gomez MV, Sanchez-Ni?o MD, Sanz AB, Ruiz-Andres O, Poveda J, Moreno JA, Egido J, Ortiz A. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant. 2012;27 Suppl 4:iv6-0. r> 12. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010;24:3562-1. rnal" href="http://dx.doi.org/10.1096/fj.09-152488" target="_blank" title="It opens in new window">CrossRef r> 13. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312-4. rnal" href="http://dx.doi.org/10.1056/NEJMra0912522" target="_blank" title="It opens in new window">CrossRef r> 14. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011;26:2567-1. rnal" href="http://dx.doi.org/10.1093/ndt/gfr144" target="_blank" title="It opens in new window">CrossRef r> 15. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-7. rnal" href="http://dx.doi.org/10.1053/ajkd.1998.v31.pm9531176" target="_blank" title="It opens in new window">CrossRef r> 16. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, London G, Gorriz JL, Floege J, Ketteler M, Ferreira A, Covic A, Rutkowski B, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998-008. rnal" href="http://dx.doi.org/10.1038/ki.2013.185" target="_blank" title="It opens in new window">CrossRef r> 17. Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial. 2011;15:176-4. rnal" href="http://dx.doi.org/10.1111/j.1744-9987.2010.00898.x" target="_blank" title="It opens in new window">CrossRef r> 18. Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S157-3. rnal" href="http://dx.doi.org/10.2215/CJN.02500607" target="_blank" title="It opens in new window">CrossRef r> 19. ref="http://clinicaltrials.gov/ct2/show/NCT01560884" class="a-plus-plus">http://clinicaltrials.gov/ct2/show/NCT01560884. Accessed 1 April 2014. r> 20. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986;315:157-1. rnal" href="http://dx.doi.org/10.1056/NEJM198607173150304" target="_blank" title="It opens in new window">CrossRef r> 21. Group KDIGOKC-MW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). Kidney Int Suppl. 2009;113:S1-30. r> 22. Foundation NK. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-01. r> 23. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. rnal" href="http://dx.doi.org/10.1136/bmj.d2040" target="_blank" title="It opens in new window">CrossRef r> 24. Bauer DC. Clinical practice. Calcium supplements and fracture prevention. N Engl J Med. 2013;369:1537-3. rnal" href="http://dx.doi.org/10.1056/NEJMcp1210380" target="_blank" title="It opens in new window">CrossRef r> 25. Gracia-Iguacel C, Gonzalez-Parra E, Rodriguez-Osorio L, Sanz AB, Almaden Y, de la Piedra C, Egido J, Rodriguez M, Ortiz A. Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema. J Bone Miner Metab. 2013;31:703-. rnal" href="http://dx.doi.org/10.1007/s00774-013-0435-z" target="_blank" title="It opens in new window">CrossRef r> 26. de Francisco AL M, Rodríguez M. Magnesium—its role in CKD. Nefrologia. 2013;33:389-9. r> 27. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85:174-1. rnal" href="http://dx.doi.org/10.1038/ki.2013.327" target="_blank" title="It opens in new window">CrossRef r> 28. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy-Deetjen ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant. 2013;28:869-8. rnal" href="http://dx.doi.org/10.1093/ndt/gfs520" target="_blank" title="It opens in new window">CrossRef r> 29. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25:3707-7. rnal" href="http://dx.doi.org/10.1093/ndt/gfq292" target="_blank" title="It opens in new window">CrossRef r> 30. Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant. 2013;28:2383-2. rnal" href="http://dx.doi.org/10.1093/ndt/gft203" target="_blank" title="It opens in new window">CrossRef r> 31. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24:278-5. rnal" href="http://dx.doi.org/10.1093/ndt/gfn488" target="_blank" title="It opens in new window">CrossRef r> 32. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A, Investigators IS. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62:771-. rnal" href="http://dx.doi.org/10.1053/j.ajkd.2013.03.023" target="_blank" title="It opens in new window">CrossRef r> 33. Di Iorio B, Bellasi A, Russo D, Investigators IS. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487-3. rnal" href="http://dx.doi.org/10.2215/CJN.03820411" target="_blank" title="It opens in new window">CrossRef r> 34. Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis. 2013;7:322-2. rnal" href="http://dx.doi.org/10.1177/1753944713513061" target="_blank" title="It opens in new window">CrossRef r> 35. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68:386-1. rnal" href="http://dx.doi.org/10.5414/CNP68386" target="_blank" title="It opens in new window">CrossRef r> 36. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130-. rnal" href="http://dx.doi.org/10.1038/sj.ki.5002466" target="_blank" title="It opens in new window">CrossRef r> 37. Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G: The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant. 2014;29(5):1061-3. r> 38. Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol. 2009;20:639-4. rnal" href="http://dx.doi.org/10.1681/ASN.2008020130" target="_blank" title="It opens in new window">CrossRef r> 39. Zaritsky JJ, Salusky IB. Ironing out the phosphorus problem. Kidney Int. 2010;77:845-. rnal" href="http://dx.doi.org/10.1038/ki.2009.560" target="_blank" title="It opens in new window">CrossRef r> 40. Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82:952-0. rnal" href="http://dx.doi.org/10.1038/ki.2012.270" target="_blank" title="It opens in new window">CrossRef r> 41. Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr. 1983;61:99-02. rnal" href="http://dx.doi.org/10.1007/BF01496662" target="_blank" title="It opens in new window">CrossRef r> 42. Yamaguchi T, Baxter JG, Maebashi N, Asano T. Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats. Ren Fail. 1999;21:453-8. rnal" href="http://dx.doi.org/10.3109/08860229909045184" target="_blank" title="It opens in new window">CrossRef r> 43. Rankin BJ, Zhu H, Webb M, Roberts NB. The development and in-vitro evaluation of novel mixed metal hydroxy-carbonate compounds as phosphate binders. J Pharm Pharmacol. 2001;53:361-. rnal" href="http://dx.doi.org/10.1211/0022357011775596" target="_blank" title="It opens in new window">CrossRef r> 44. Gruenhagen SE, Schulze DG, Chansiri G, Hem KJ, White JL, Hem SL. Effect of sorbitol on the phosphate adsorptive capacity of ferrihydrite suspensions. Pharm Dev Technol. 1997;2:81-. rnal" href="http://dx.doi.org/10.3109/10837459709022611" target="_blank" title="It opens in new window">CrossRef r> 45. Spengler K, Follmann H, Boos KS, Seidel D, von der Haar F, Elsner R, Maywald F. Cross-linked iron dextran is an efficient oral phosphate binder in the rat. Nephrol Dial Transplant. 1996;11:808-2. rnal" href="http://dx.doi.org/10.1093/oxfordjournals.ndt.a027403" target="_blank" title="It opens in new window">CrossRef r> 46. Baxter J, Shimizu F, Takiguchi Y, Wada M, Yamaguchi T. Effect of iron(III) chitosan intake on the reduction of serum phosphorus in rats. J Pharm Pharmacol. 2000;52:863-4. rnal" href="http://dx.doi.org/10.1211/0022357001774552" target="_blank" title="It opens in new window">CrossRef r> 47. Bürger C, Valcarenghi D, Sandri S, Rodrigues CA. Cross-linking chitosan-Fe(III), an oral phosphate binder: studies in vitro and in vivo. Int J Pharm. 2001;223:29-3. rnal" href="http://dx.doi.org/10.1016/S0378-5173(01)00727-X" target="_blank" title="It opens in new window">CrossRef r> 48. Zhu H, Webb M, Buckley J, Roberts NB. Different Mg to Fe ratios in the mixed metal MgFe hydroxy-carbonate compounds and the effect on phosphate binding compared with established phosphate binders. J Pharm Sci. 2002;91:53-6. rnal" href="http://dx.doi.org/10.1002/jps.1170" target="_blank" title="It opens in new window">CrossRef r> 49. ref="http://clinicaltrials.gov/show/NCT00841126" class="a-plus-plus">http://clinicaltrials.gov/show/NCT00841126. Accessed 1 April 2014. r> 50. ref="http://clinicaltrials.gov/ct2/show/NCT00844662" class="a-plus-plus">http://clinicaltrials.gov/ct2/show/NCT00844662. Accessed 1 April 2014. r> 51. ref="http://clinicaltrials.gov/ct2/show/NCT00358722" class="a-plus-plus">http://clinicaltrials.gov/ct2/show/NCT00358722. Accessed 1 April 2014. r> 52. McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ. Iron–magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:401-. rnal" href="http://dx.doi.org/10.2215/CJN.02630608" target="_blank" title="It opens in new window">CrossRef r> 53. ref="http://investor.opko.com/releasedetail.cfm?ReleaseID=745014" class="a-plus-plus">http://investor.opko.com/releasedetail.cfm?ReleaseID=745014. Accessed 1 April 2014. r> 54. ref="http://www.cytochroma.com/pipeline/product_candidates.html" class="a-plus-plus">http://www.cytochroma.com/pipeline/product_candidates.html. Accessed 1 April 2014. r> 55. Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77:897-03. rnal" href="http://dx.doi.org/10.1038/ki.2010.23" target="_blank" title="It opens in new window">CrossRef r> 56. Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16:743-0. rnal" href="http://dx.doi.org/10.1111/j.1440-1797.2011.01509.x" target="_blank" title="It opens in new window">CrossRef r> 57. ref="http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4663" class="a-plus-plus">http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4663. Accessed 1 April 2014. r> 58. ref="http://www.novartis.com/downloads/newsroom/corporate-publications/Novartis-20-F-2010.pdf" class="a-plus-plus">http://www.novartis.com/downloads/newsroom/corporate-publications/Novartis-20-F-2010.pdf. Accessed 1 April 2014. r> 59. ref="http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4664" class="a-plus-plus">http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4664. Accessed 1 April 2014. r> 60. Fukagawa M, Kasuga H, Joseph D, Sawata H, Junge G, Moore A, Akiba T. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. Clin Exp Nephrol. 2014;18:135-3. rnal" href="http://dx.doi.org/10.1007/s10157-013-0815-7" target="_blank" title="It opens in new window">CrossRef r> 61. Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol. 1999;10:1274-0. r> 62. Iida A, Kemmochi Y, Kakimoto K, Tanimoto M, Mimura T, Shinozaki Y, Uemura A, Matsuo A, Matsushita M, Miyamoto K. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013;37:346-8. rnal" href="http://dx.doi.org/10.1159/000348805" target="_blank" title="It opens in new window">CrossRef r> 63. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002;17:265-0. rnal" href="http://dx.doi.org/10.1093/ndt/17.2.265" target="_blank" title="It opens in new window">CrossRef r> 64. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Group CS. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012;121:c25-. rnal" href="http://dx.doi.org/10.1159/000341922" target="_blank" title="It opens in new window">CrossRef r> 65. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36:478-7. rnal" href="http://dx.doi.org/10.1159/000344008" target="_blank" title="It opens in new window">CrossRef r> 66. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013;61:759-6. rnal" href="http://dx.doi.org/10.1053/j.ajkd.2012.11.041" target="_blank" title="It opens in new window">CrossRef r> 67. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Group CS. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int. 2013;17:67-4. rnal" href="http://dx.doi.org/10.1111/j.1542-4758.2012.00711.x" target="_blank" title="It opens in new window">CrossRef r> 68. ref="http://www.keryx.com/press-releases/" class="a-plus-plus">http://www.keryx.com/press-releases/. Accessed 1 April 2014. r> 69. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(5):1053-0. r> 70. Mutell R, Rubin JL, Bond TC, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013;6:79-7. r> 71. ref="http://www.jt.com/media/press_releases/2014/pdf/20140117_04.pdf" class="a-plus-plus">http://www.jt.com/media/press_releases/2014/pdf/20140117_04.pdf. Accessed 1 April 2014. r> 72. ref="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001213-PIP02-12/pip_001071.jsp&mid=WC0b01ac058001d129" class="a-plus-plus">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001213-PIP02-12/pip_001071.jsp&mid=WC0b01ac058001d129. Accessed 1 April 2014. r> 73. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9:543-2. rnal" href="http://dx.doi.org/10.2215/CJN.05170513" target="_blank" title="It opens in new window">CrossRef r> 74. ref="http://www.elsevierbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2013/December/12213%20Velphoro%20approval%20letter.pdf" class="a-plus-plus">http://www.elsevierbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2013/December/12213%20Velphoro%20approval%20letter.pdf. Accessed 1 April 2014. r> 75. ref="http://www.viforpharma.com/en/Media/mediareleases/2013/20131128_velphoro-us.php" class="a-plus-plus">http://www.viforpharma.com/en/Media/mediareleases/2013/20131128_velphoro-us.php. Accessed 1 April 2014. r> 76. ref="http://www.fda.gov/downloads/drugs/informationondrugs/ucm086233.pdf" class="a-plus-plus">http://www.fda.gov/downloads/drugs/informationondrugs/ucm086233.pdf. Accessed 1 April 2014. r> 77. Phan O, Maillard M, Peregaux C, Mordasini D, Stehle JC, Funk F, Burnier M. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013;346:281-. rnal" href="http://dx.doi.org/10.1124/jpet.113.204792" target="_blank" title="It opens in new window">CrossRef r> 78. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999;14:863-. rnal" href="http://dx.doi.org/10.1093/ndt/14.4.863" target="_blank" title="It opens in new window">CrossRef r> 79. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010;74:4-1. rnal" href="http://dx.doi.org/10.5414/CNP74004" target="_blank" title="It opens in new window">CrossRef r> 80. Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8:280-. rnal" href="http://dx.doi.org/10.2215/CJN.08230811" target="_blank" title="It opens in new window">CrossRef r> 81. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014. r> 82. ref="https://www.velphoro.us/downloads/prescribing-information.pdf" class="a-plus-plus">https://www.velphoro.us/downloads/prescribing-information.pdf. Accessed 1 April 2014. r> 83. Van de Vyver FL, Visser WJ, D’Haese PC, De Broe ME. Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant. 1990;5:781-. rnal" href="http://dx.doi.org/10.1093/ndt/5.9.781" target="_blank" title="It opens in new window">CrossRef r> 84. Kirchner S, Muduli A, Casirola D, Prum K, Douard V, Ferraris RP. Luminal fructose inhibits rat intestinal sodium-phosphate cotransporter gene expression and phosphate uptake. Am J Clin Nutr. 2008;87:1028-8. r> 85. Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D. 2013;13:165-3. rnal" href="http://dx.doi.org/10.1007/s40268-013-0024-6" target="_blank" title="It opens in new window">CrossRef r> 86. de Francisco AL. Phosphate binders. Is selection determined by price? Yes. Nefrologia. 2012;32:235-. r>
• 作者单位：Dimitra Nastou (1) r> Beatriz Fernández-Fernández (2) (3) r> Usama Elewa (2) (3) r> Liliana González-Espinoza (2) (3) r> Emilio González-Parra (2) (3) r> Maria D. Sanchez-Ni?o (3) (4) r> Alberto Ortiz (2) (3) (5) r>r>1. Hellenic Red Cross Hospital, Athens, Greece r> 2. Unidad de Diálisis, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040, Madrid, Spain r> 3. REDINREN, Madrid, Spain r> 4. IDIPAZ, Madrid, Spain r> 5. IRSIN Universidad Autónoma de Madrid, Madrid, Spain r>
• ISSN：1179-1950

文摘

Phosphate excess is associated with increased mortality in patients with chronic kidney disease (CKD) and has recently been linked to accelerated aging. Oral phosphate binders are prescribed to patients with CKD to prevent absorption of dietary phosphate. Currently available binders have been associated with impaired outcomes (calcium-based binders) or are expensive (non-calcium-based binders). Iron-based phosphate binders represent a new class of phosphate binders. Four iron-based phosphate binders have undergone testing in clinical trials. The development of fermagate and SBR759 is currently on hold due to suboptimal and adverse effect profiles in at least some clinical trials. Ferric citrate and sucroferric oxyhydroxide (PA21) are at different stages of application for regulatory approval after being found safe and efficacious in decreasing serum phosphate. Iron from ferric citrate is more readily absorbed than that from sucroferric oxyhydroxide. Sucroferric oxyhydroxide was launched in the USA in 2014 for the treatment of hyperphosphatemia in adult dialysis patients. Ferric citrate may be more suited for chronic treatment of hyperphosphatemia in CKD patients requiring iron supplements but its use may have to be limited in time because of potential for iron overload in patients not needing iron or not receiving erythropoiesis-stimulating agents. In contrast, sucroferric oxyhydroxide may be more suited for hyperphosphatemic CKD patients not requiring iron supplements.